secwatch.observer — SEC 8-K summary
======================================

Issuer:     Zai Lab Ltd (ZLAB)
CIK:        0001704292
Form:       8-K
Filed at:   2024-02-27T23:59:59+00:00
Accession:  0001628280-24-007217
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Zai Lab FY2023 product revenue $266.7M (+25% YoY); VYVGART launch drives 2024 outlook >$70M
--------------------------------------------------------------------------------

- Product revenue $266.7M (+25% YoY; +31% CER); net loss narrowed to $334.6M from $443.3M.
- VYVGART launched Sept 2023; 2023 revenue $10M; ~1,000 patients treated in Jan 2024; 2024 guidance >$70M.
- ZEJULA $168.8M (+16% YoY); OPTUNE $47.0M (flat); QINLOCK $19.2M (+29%); NUZYRA $21.7M (+316%).
- Cash $807.6M (Dec 31, 2023) vs $1.0B year prior; R&D down, SG&A up on VYVGART launch.
- Targeting profitability by end of 2025; regulatory submissions expected for 4 new products in 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1704292/000162828024007217/0001628280-24-007217-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1704292/000162828024007217/zlab-20240227.htm
  HTML page:      https://secwatch.observer/filing/0001628280-24-007217

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer